Johnson & Johnson Lung Cancer Innovation Science Grants
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with Unit
Memorial Deadline: Thursday 11th, July 2019
External Deadline: Friday 19th, July 2019
Description
The AACR-Johnson & Johnson Lung Cancer Innovation Science Grants represent a joint effort to address the need for promoting and supporting collaborative cancer research in areas that include digital therapeutics and smoking cessation biomarkers/behavioral phenotyping, to bolster our understanding of how lung cancer can be successfully intercepted. Prioritized areas of interest may include: clinical trials that would identify unique high-risk patients for lung cancer and demonstrate sustained efficacy through the measurement of both quit rates, as well as disease-related biomarkers; clinical trials that would identify digital therapeutics focused on smoking avoidance for first-time smokers or for former smokers; these therapeutics may consider the impact of social engagement, gaming, and other content relevant for populations at a risk of starting or resuming their smoking habit. The inclusion of a strategic plan for clinical confirmation of the digital therapeutic study is recommended.
This project must be implemented by a multi-institutional team, composed of Principal Investigators from at least two, but no more than three, different institutions and include a clinical component with an endpoint relevant to improving the detection or treatment of lung cancer. The Grant will provide $1 million in funding for direct and indirect expenses related to each research project over a three-year timeframe.
For additional information click here.